Lung Cancer Considered

This episode reviews the IASLC 2025 Hot Topic in Basic and Translational Science Conference, which focused on unraveling precancer and early-stage lung cancer, a theme that really captures where the field is heading. Instead of reacting to advanced disease.

Guests:
Dr. Triparna Sen, a professor of Internal Medicine at The Ohio State University and the director of the Lung Cancer Preclinical Therapeutics Platform at the OSUCCC – James. She also serves as the associate director of research for the Division of Medical Oncology. Her research focuses on understanding and therapeutically targeting mechanisms of therapy resistance and lineage plasticity in lung cancer, with a primary emphasis on small cell lung cancer (SCLC) and biologically aggressive subsets of non-small cell lung cancer.

Dr. Aaron Tan is a physician-scientist whose work bridges early detection, translational biology, and clinical relevance in lung cancer. Dr. Tan is a Medical Oncologist at the National Cancer Centre Singapore (NCCS), where he is involved in early drug development, genomics with a focus on EGFR mutated lung cancer, and clinical implementation of liquid biopsy including for advanced lung cancer and MRD in early-stage lung cancer.

As part of IASLC’s Lung Cancer Considered World Language Series, guest host Dr. Maria Cecilia Mathias leads a discussion in Portuguese about the junior faculty perspective with Dr. Maria Thereza Starling and Dr. Paula Duarte.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu is joined by CNN Medical Correspondent Meg Tirrell and WTOP reporter Neal Augenstein to discuss the role of the media in lung cancer awareness and perception. Traditional media, including television and radio, do much to shape the public perception of lung cancer and healthcare in general. Meg Tirrell and Neal Augenstein share their experiences reporting in the health sector, establishing trust with their audiences in the face of uncertainty, and distilling complex medical information to the general public.

Since the first immunotherapy agent for lung cancer was approved in 2015, this class of drugs has captured the imagination and the narrative for the treatment of driver negative lung cancer. Immunotherapy is now the standard of care for most patients with lung cancer in some form. And while not all patients benefit, those that do, have the chance for transformative benefit. In today’s episode, we focus not on the benefit of immunotherapy, which can be massive, but on the toxicity of immunotherapy.

Guest: Dr. Jarushka Naidoo, a consultant medical oncologist at Beaumont Hospital Dublin and a Professor in the Royal College of Surgeons in Ireland. She currently serves as national lung cancer lead for Cancer Trials Ireland and serves on several international guideline panels including ASCO and SITC

The FDA has approved subcutaneous amivantamab. Join host Dr. Narjust Florez and guests, Dr. Natasha Leighl and Dr. Federico Cappuzzo, as they explore the science and convenience factor, as well as what this shift means for patients, clinicians, and oncology practice.